Improved quality of life in patients treated with lebrikizumab monotherapy is mediated by improvements in itch and sleep: results from two phase III trials in patients with moderate-to-severe atopic dermatitis

Gil Yosipovitch; Marjolein de Bruin-Weller; Marni Wiseman; Jesper Elberling; Jan Gutermuth; Evangeline Pierce; Sonia Montmayeur; Fan Emily Yang; Yuxin Ding; Laia Bardolet; Sarah Chisolm

doi:10.1093/ced/llae541

Improved quality of life in patients treated with lebrikizumab monotherapy is mediated by improvements in itch and sleep: results from two phase III trials in patients with moderate-to-severe atopic dermatitis

Gil Yosipovitch
, Marjolein de Bruin-Weller
, Marni Wiseman
, Jesper Elberling
, Jan Gutermuth
, Evangeline Pierce
, Sonia Montmayeur
, Fan Emily Yang
, Yuxin Ding
, Laia Bardolet
, Sarah Chisolm

Research output: Contribution to journal › Article › Academic › peer-review

10 Downloads (Pure)

Abstract

Pruritus is a hallmark symptom of atopic dermatitis (AD) and is known to worsen patients' health-related quality of life. Lebrikizumab is a high-affinity monoclonal antibody that binds interleukin-13, a key cytokine implicated in AD. This study includes data from two phase III randomized controlled trials that assessed the efficacy and safety of lebrikizumab in patients with moderate-to-severe AD, ADvocate1 (NCT04146363) and ADvocate2 (NCT04178967). We report a post hoc analysis to quantify the effect of lebrikizumab vs. placebo on the Dermatology Life Quality Index (DLQI) mediated indirectly through its effect on patient-reported outcomes, specifically itch and the interference of itch on sleep. Approximately two-thirds of the improvement at week 16 in DLQI experienced by patients treated with lebrikizumab vs. patients treated with placebo was mediated by improvements in itch and the interference of itch on sleep.

Original language	English
Pages (from-to)	1188-1192
Number of pages	5
Journal	Clinical and experimental dermatology
Volume	50
Issue number	6
Early online date	16 Dec 2024
DOIs	https://doi.org/10.1093/ced/llae541
Publication status	Published - Jun 2025

Access to Document

10.1093/ced/llae541Licence: CC BY-NC

llae541Final published version, 844 KBLicence: CC BY-NC

Fingerprint

Dive into the research topics of 'Improved quality of life in patients treated with lebrikizumab monotherapy is mediated by improvements in itch and sleep: results from two phase III trials in patients with moderate-to-severe atopic dermatitis'. Together they form a unique fingerprint.

Cite this

Yosipovitch, G., de Bruin-Weller, M., Wiseman, M., Elberling, J., Gutermuth, J., Pierce, E., Montmayeur, S., Yang, F. E., Ding, Y., Bardolet, L., & Chisolm, S. (2025). Improved quality of life in patients treated with lebrikizumab monotherapy is mediated by improvements in itch and sleep: results from two phase III trials in patients with moderate-to-severe atopic dermatitis. Clinical and experimental dermatology, 50(6), 1188-1192. https://doi.org/10.1093/ced/llae541

@article{2678d0c35c17480c93c16f37f0aabf1d,

title = "Improved quality of life in patients treated with lebrikizumab monotherapy is mediated by improvements in itch and sleep: results from two phase III trials in patients with moderate-to-severe atopic dermatitis",

abstract = "Pruritus is a hallmark symptom of atopic dermatitis (AD) and is known to worsen patients' health-related quality of life. Lebrikizumab is a high-affinity monoclonal antibody that binds interleukin-13, a key cytokine implicated in AD. This study includes data from two phase III randomized controlled trials that assessed the efficacy and safety of lebrikizumab in patients with moderate-to-severe AD, ADvocate1 (NCT04146363) and ADvocate2 (NCT04178967). We report a post hoc analysis to quantify the effect of lebrikizumab vs. placebo on the Dermatology Life Quality Index (DLQI) mediated indirectly through its effect on patient-reported outcomes, specifically itch and the interference of itch on sleep. Approximately two-thirds of the improvement at week 16 in DLQI experienced by patients treated with lebrikizumab vs. patients treated with placebo was mediated by improvements in itch and the interference of itch on sleep.",

author = "Gil Yosipovitch and \{de Bruin-Weller\}, Marjolein and Marni Wiseman and Jesper Elberling and Jan Gutermuth and Evangeline Pierce and Sonia Montmayeur and Yang, \{Fan Emily\} and Yuxin Ding and Laia Bardolet and Sarah Chisolm",

note = "Publisher Copyright: {\textcopyright} 2024 The Author(s).",

year = "2025",

month = jun,

doi = "10.1093/ced/llae541",

language = "English",

volume = "50",

pages = "1188--1192",

journal = "Clinical and experimental dermatology",

issn = "0307-6938",

publisher = "Oxford University Press",

number = "6",

}

Yosipovitch, G, de Bruin-Weller, M, Wiseman, M, Elberling, J, Gutermuth, J, Pierce, E, Montmayeur, S, Yang, FE, Ding, Y, Bardolet, L & Chisolm, S 2025, 'Improved quality of life in patients treated with lebrikizumab monotherapy is mediated by improvements in itch and sleep: results from two phase III trials in patients with moderate-to-severe atopic dermatitis', Clinical and experimental dermatology, vol. 50, no. 6, pp. 1188-1192. https://doi.org/10.1093/ced/llae541

Improved quality of life in patients treated with lebrikizumab monotherapy is mediated by improvements in itch and sleep: results from two phase III trials in patients with moderate-to-severe atopic dermatitis. / Yosipovitch, Gil; de Bruin-Weller, Marjolein; Wiseman, Marni et al.
In: Clinical and experimental dermatology, Vol. 50, No. 6, 06.2025, p. 1188-1192.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Improved quality of life in patients treated with lebrikizumab monotherapy is mediated by improvements in itch and sleep

T2 - results from two phase III trials in patients with moderate-to-severe atopic dermatitis

AU - Yosipovitch, Gil

AU - de Bruin-Weller, Marjolein

AU - Wiseman, Marni

AU - Elberling, Jesper

AU - Gutermuth, Jan

AU - Pierce, Evangeline

AU - Montmayeur, Sonia

AU - Yang, Fan Emily

AU - Ding, Yuxin

AU - Bardolet, Laia

AU - Chisolm, Sarah

PY - 2025/6

Y1 - 2025/6

N2 - Pruritus is a hallmark symptom of atopic dermatitis (AD) and is known to worsen patients' health-related quality of life. Lebrikizumab is a high-affinity monoclonal antibody that binds interleukin-13, a key cytokine implicated in AD. This study includes data from two phase III randomized controlled trials that assessed the efficacy and safety of lebrikizumab in patients with moderate-to-severe AD, ADvocate1 (NCT04146363) and ADvocate2 (NCT04178967). We report a post hoc analysis to quantify the effect of lebrikizumab vs. placebo on the Dermatology Life Quality Index (DLQI) mediated indirectly through its effect on patient-reported outcomes, specifically itch and the interference of itch on sleep. Approximately two-thirds of the improvement at week 16 in DLQI experienced by patients treated with lebrikizumab vs. patients treated with placebo was mediated by improvements in itch and the interference of itch on sleep.

AB - Pruritus is a hallmark symptom of atopic dermatitis (AD) and is known to worsen patients' health-related quality of life. Lebrikizumab is a high-affinity monoclonal antibody that binds interleukin-13, a key cytokine implicated in AD. This study includes data from two phase III randomized controlled trials that assessed the efficacy and safety of lebrikizumab in patients with moderate-to-severe AD, ADvocate1 (NCT04146363) and ADvocate2 (NCT04178967). We report a post hoc analysis to quantify the effect of lebrikizumab vs. placebo on the Dermatology Life Quality Index (DLQI) mediated indirectly through its effect on patient-reported outcomes, specifically itch and the interference of itch on sleep. Approximately two-thirds of the improvement at week 16 in DLQI experienced by patients treated with lebrikizumab vs. patients treated with placebo was mediated by improvements in itch and the interference of itch on sleep.

U2 - 10.1093/ced/llae541

DO - 10.1093/ced/llae541

M3 - Article

C2 - 39680511

SN - 0307-6938

VL - 50

SP - 1188

EP - 1192

JO - Clinical and experimental dermatology

JF - Clinical and experimental dermatology

IS - 6

ER -

Yosipovitch G, de Bruin-Weller M, Wiseman M, Elberling J, Gutermuth J, Pierce E et al. Improved quality of life in patients treated with lebrikizumab monotherapy is mediated by improvements in itch and sleep: results from two phase III trials in patients with moderate-to-severe atopic dermatitis. Clinical and experimental dermatology. 2025 Jun;50(6):1188-1192. Epub 2024 Dec 16. doi: 10.1093/ced/llae541